TABLE 4.

Predicted Cumulative Direct Health Care Cost Differences by Anti-CCP Category^a

Cumulative Years
Number	1	1-2	1-3	1-4	1-5	1-6	1-7	1-8
	2,448	1,882	1,466	1,117	809	539	278	83
Total health care costs, $
Anti-CCP positive	7,465	24,223	42,235	61,248	80,038	101,400	121,210	138,011
Anti-CCP negative	5,302	18,890	33,208	47,159	60,681	74,280	91,029	108,250
Incremental costsb	2,163	5,333	9,027	14,089	19,357	27,119	30,180	29,760
Prescription costs, $
Anti-CCP positive	6,671	18,722	31,662	45,292	59,467	75,033	90,162	104,351
Anti-CCP negative	4,172	11,667	20,704	29,485	37,838	46,611	56,613	68,482
Incremental costsb	2,499	7,054	10,957	15,806	21,628	28,422	33,549	35,870
Laboratory costs, $
Anti-CCP positive	398	1,288	2,173	3,070	3,920	4,739	5,588	6,329
Anti-CCP negative	215	1,042	1,826	2,634	3,429	4,190	5,125	6,215
Incremental costsb	183	246	348	435	490	550	463	115
Rheumatologist visit costs, $
Anti-CCP positive	298	667	1,023	1,349	1,705	1,988	2,248	2,580
Anti-CCP negative	222	480	712	958	1,168	1,362	1,604	1,851
Incremental costsb	76	187	311	390	537	626	644	729
Outpatient office visit costs, $
Anti-CCP positive	338	2,010	3,777	5,546	7,361	9,402	11,126	12,683
Anti-CCP negative	326	2,417	4,388	6,512	8,663	10,773	13,538	16,016
Incremental costsb	12	-407	-611	-965	-1,302	-1,371	-2,412	-3,333

^a Cost differences are shown in 2015 U.S. dollars.

^b Incremental costs = anti-CCP positive – anti-CCP negative. CCP= cyclic citrullinated peptide.